



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:		203057	METAGENICS TOCOCARE
ARTG entry for	Medicine Listed		
Sponsor	Metagenics (Aust) Pty Ltd		
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia		
ARTG Start Date	17/11/2012		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicines		
Conditions			
Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.			
The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.			
The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.			
Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.			
Products			
1 . METAGENICS TOCOCARE			
Product Type	Single Medicine Product	Effective Date	17/02/2025
Permitted Indications			
Helps reduce/decrease free radical damage to body cells Maintain/support general health and wellbeing Maintain/support cardiovascular system health			
Indication Requirements			
Product presentation must not imply or refer to serious cardiovascular conditions.			
Standard Indications			
No Standard Indications included on Record			
Specific Indications			
No Specific Indications included on Record			
Warnings			
If symptoms persist consult your healthcare practitioner (or words to that effect).			
Additional Product information			
Pack Size/Poison information			
Pack Size		Poison Schedule	
Components			
1 . Formulation 1			
Dosage Form	Capsule, soft		
Route of Administration	Oral		
Visual Identification			
Active Ingredients			
Citrus bioflavonoids extract		270 mg	

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

palm tocotrienols complex

18 mg

Other Ingredients (Excipients)

Colour

Gelatin

glycerol

lecithin

purified water

Soya Oil

yellow beeswax

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary